Zensar Technologies today announced the successful 'go live' of the SAP ERP and CRM at BDI Pharma. The project was delivered through a collaborative engagement between BDI Pharma and Zensar Technologies, and their teams of SAP and industry experts.
This deployment has been achieved with the use 'ZenLife', a proprietary accelerator tool, and the use of various solution frameworks, regulatory expertise, and consulting capabilities in life sciences, which has resulted in significant cost savings and increased capabilities and efficiency for sales and distribution.
ZenLife is a ready-to-use industry specific templatised SAP solution for pharmaceutical companies, covering about 80%-85% of the major business processes and manufacturing operations such as OTC, private label, generics, manufacturing/distribution and sale of products ranging from API to formulations (all kinds of dosage forms).
The solution is comprehensive and validated for the pharmaceutical industry. As a full implementation and testing partner for SAP applications worldwide, Zensar's SAP practice offers complete, end-to-end services extending from pre-implementation planning through maintenance, support, and upgrade.
On the successful completion of the project, Chief Executive and Global Head MRM Nitin Parab said: “Zensar's SAP Methodology is refined overtime over multiple projects for multi-site global execution. Today, Zensar's SAP Pharma Solution 'ZenLife' is rated among the best in the industry, and has a significant market share in SAP's Pharmaceuticals Installations. Our seamless transition and installation capabilities have already shown results in the form of cost savings for BDI Pharma, and we hope to grow this engagement further in the years to come.”
“The level of expertise demonstrated by Zensar, in combination with the entire organisation's proactive approach to issue resolution and system modification, has been critical to the success of our conversion to SAP,” stated William A Shirey III, Executive Vice-President at BDI Pharma. “The collaborative environment established between Zensar and BDI Pharma integration managers has been remarkable, and has made the entire process a true team effort.”
BDI has also selected Zensar to deliver the Business Intelligence Strategy and SAP Business Objects Implementation for reporting and dash-boarding. This effort has been planned for 'go live' in the coming months.
Zensar Technologies is a Gold Certified and Strategic Value-Added Reseller (SVAR) SAP Partner, with over 10 years of deep expertise in developing and delivering SAP services, which help clients adopt and extend technology to drive business transformation and achieve their business goals.
Zensar offers value-added preconfigured SAP solutions to minimise clients' total cost of ownership, including development and support. These industry specific and preconfigured solutions are available with built-in content, tools and methodologies for a cost-effective implementation. Leveraging a unique global development model, Zensar's SAP Practice delivers functional and technical expertise amplified by best practices for implementation, maintenance, upgrade and enhancement services for end-to-end solutions.
Share
Zensar Technologies (www.zensar.com)
Zensar Technologies is among the top 20 software services providers from India. Zensar is the world's first enterprise-wide SEI CMM Level 5 company and was also later certified as a CMMI Level 5 company with industry expertise that spans retail, manufacturing, banking, insurance, energy and utilities, media and connected services - government, education and healthcare. An RPG Group company, Zensar has more than 6 000 employees with sales and operations presence across US, UK, Germany, Sweden, Finland, Middle East, South Africa, Singapore, Australia, China and Japan. The company delivers comprehensive services in mission-critical applications, enterprise applications, e-business, BPO and knowledge services. The company has developed tools and methodologies, including the proprietary Solution Blue Print (SBP), which enables its clients with innovative business solutions and a rapid 'go-to-market' capability. The company supports Fortune 500 clients with software business solutions that help them compete in the digital economy.
BDI Pharma (www.bdipharma.com)
Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians - 4legpharma.com; product consignment - consignadvantage.com; flu pre-booking and general vaccine ordering - securivax.com; and purchasing/reward programs - qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large. BDI Pharma's portfolio includes branded and generic specialty biopharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognised as an “ADR”, or Authorised Distributor of Record, for all of the manufacturers it represents.
Safe harbour
Certain statements in this release concerning our future growth prospects are forward-looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorised use of our intellectual property and general economic conditions affecting our industry. The company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.
Editorial contacts